Alexander Mark Schobel, Chief Innovation/Tech Officer at Aquestive Therapeutics, Inc. (AQST), sold 50,000 shares at $6.00 ($300K) on 2024-03-15, disclosed to the SEC on 2024-03-19.
Scheduled sale ($300k) by Chief Innovation/Tech Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AQST | SELL | 2021-02-10 | $236K | — | Filing → |
| AQST | SELL | 2021-02-09 | $265K | — | Filing → |
| AQST | SELL | 2020-05-11 | $200K | — | Filing → |